Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MCET volume is going crazy... may run even more
MCET looking strong now
MCET in again for a rebound
MCET out for now... nice run from 0.009
RHDC.pk next potential bagger
MCET usually going to near 0.03 on news
MCET about to go nutso...
MCET multibagger on the make????
MCET patent news:
MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
MultiCell Strengthens Its Liver Cancer Drug Target Identification and Cancer Stem Cell Research Program
Press Release
Source: MultiCell Technologies, Inc.
On Thursday August 20, 2009, 8:00 am EDT
Buzz up! 0 Print
Companies:MultiCell Technologies, Inc.
WOONSOCKET, R.I., Aug. 20 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET - News) announced today it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.
Related Quotes
Symbol Price Change
MCET.OB 0.01 0.00
{"s" : "mcet.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""} The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
MultiCell also owns exclusive worldwide rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of human liver stem cells. MultiCell previously announced it had entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of human liver stem cells and human liver cancer.
The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. "MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer," said Jerry Newmin, Chairman & CEO of MultiCell Technologies. "We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets."
The National Cancer Institute (NCI) in 2008 stated there were approximately 21,400 new cases of hepatocellular carcinoma and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.
MCET rocking on news...
RHDC.pk ready to go... nice volume @hod
IGAI new round starting...volume hitting
SCLL another upleg
RHDC.pk slowly breaking out..check!
IGAI lotto play heating up...
SCLL on the move again today
BCLI another stem play starting
SCLL rocking...MCET next
SCLL going...watch MCET this one usually following scll
SCLL and MCET... watch... moving
RHDC.pk... green now
MCET slowly moving up last 2-days
PRMO lotto tikett on the watch...volume hitting the ask
MCET bid ut and new high
SPNG nice... moving up
SPNG trending up
MYNG huge volume today...
PTN nice runner today
MYNG
MCET bid ut
IVOT slowly but moving up
MCET looking ready... stem play
on oxpa momo...watch other stem play's ACTC, BCLI, MCET to take off
IVOT is ready... take a look at the trades last few days.. no sellers
IVOT is ready... take a look at the trades last few days.. no sellers
INHX naz low float bio play... nice bids going on
RHDC.pk day high 0.08$ looking better and better..solid uptrend last few days
EPCG.pk huge volume now on this lotto play...
EPCG new lotto tikett.. huge volume hitting
INHX low float naz bio play moving a bit